Hydrogen in Patients With Corticosteroid-Refractory/Dependent Chronic Graft-Versus-Host-Disease: A Single-Arm, Multicenter, Open-Label, Phase 2 Trial.
Liren Qian, Miao Liu, Jianliang Shen, Jian Cen, Defeng Zhao · Frontiers in immunology · 2020
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In 24 patients, no significant toxicity was observed. This open-label study supports molecular hydrogen's therapeutic potential for the condition studied, while larger randomized, placebo-controlled studies are needed to confirm the finding.
What the Researchers Studied
24 patients
How the Study Was Conducted
Human clinical study
How Molecular Hydrogen Was Used
Patients received hydrogen-rich water 4ml/kg orally three times a day.
What the Researchers Found
No significant toxicity was observed.